Breaking News, Collaborations & Alliances

Valo Selects Exothera to Develop Large-scale Oncolytic Adenovirus Manufacturing

The CDMO will perform tech transfer, analytical development, and scale-up to initiate manufacturing at its GMP facility in Jumet, Belgium.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Valo Therapeutics (ValoTx), a developer of immunotherapy platforms for cancer and infectious diseases, has selected Exothera, a full service contract development and manufacturing organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102. ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated C...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters